Scaling Of Impingement Jets Mixing For The Production Of Lipid Nanoparticle Drugs

Many pharmaceutical companies are focused on using lipid nanoparticles (LNPs) to deliver nucleic acids, with COVID-19 vaccines being the most well-known example. LNPs are made by quickly mixing an aqueous stream of nucleic acids (like mRNA) with a stream of lipids in alcohol. This mixing process needs to be reliable, scalable, and able to produce consistent results.

This case study explores the application of KNAUER's Impingement Jets Mixing (IJM) technology in LNP production, highlighting its scalability and efficiency. The study, conducted in partnership with two companies, showcases the impact of varying operating parameters on LNP quality and the effects of production scale-up. IJM technology has been successfully used to create LNPs of the right size and consistency, effectively encapsulating various nucleic acids. The technology works well across a range of production scales, from small (1 mL/min) to large (1 L/min), making it easy to transition from lab work to large-scale manufacturing. This method offers a robust alternative to more complex mixing methods.

To learn more about this exciting development in LNP production, access the full case study here.